A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
Completed
Shire
Phase 1
2019-05-14
The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a
single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by
prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
Completed
Shire
Phase 3
2019-12-12
The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and
efficacy of lanadelumab in Japanese participants with HAE Type I or II.
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Recruiting
Takeda Development Center Americas, Inc.
Phase 3
2021-02-05
The purpose of this study is to evaluate the long-term safety and efficacy of repeated
subcutaneous (SC) administration of lanadelumab in adolescents and adults with
non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303
(NCT04206605).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
